Unknown

Dataset Information

0

Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer.


ABSTRACT: We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT (60-63 Gy (relative biological effectiveness equivalents; RBE)/20-21 fractions) (n = 343) or NFPT (74-78 Gy (RBE)/37-39 fractions) (n = 296) between 2013 and 2016 were analyzed. The minimum clinically important difference (MCID) threshold was defined as one-half of a standard deviation of the baseline value. The median follow-up was 56 months and 83% completed questionnaires at 36 months. Clinically meaningful score deterioration was observed in the urinary domain at 1 month in both groups and in the sexual domain at 6-36 months in the NFPT group, but not observed in the bowel domain. At 36 months, the mean score change for urinary summary was -0.3 (MHPT) and -1.6 points (NFPT), and that for bowel summary was +0.1 and -2.0 points; the proportion of patients with MCID was 21% and 24% for urinary summary and 18% and 29% for bowel summary. Overall, MHPT had small negative impacts on QOL over three years, and the QOL after MHPT and NFPT was similar.

SUBMITTER: Nakajima K 

PROVIDER: S-EPMC8833499 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Patient-Reported Quality of Life Outcomes after Moderately Hypofractionated and Normofractionated Proton Therapy for Localized Prostate Cancer.

Nakajima Koichiro K   Iwata Hiromitsu H   Hattori Yukiko Y   Nomura Kento K   Hayashi Kensuke K   Toshito Toshiyuki T   Umemoto Yukihiro Y   Hashimoto Shingo S   Ogino Hiroyuki H   Shibamoto Yuta Y  

Cancers 20220120 3


We retrospectively evaluated the three-year patient-reported quality of life (QOL) after moderately hypofractionated proton therapy (MHPT) for localized prostate cancer in comparison with that after normofractionated PT (NFPT) using the Expanded Prostate Cancer Index Composite-50. Patients who received MHPT (60-63 Gy (relative biological effectiveness equivalents; RBE)/20-21 fractions) (<i>n</i> = 343) or NFPT (74-78 Gy (RBE)/37-39 fractions) (<i>n</i> = 296) between 2013 and 2016 were analyzed.  ...[more]

Similar Datasets

| S-EPMC9425455 | biostudies-literature
| S-EPMC9163454 | biostudies-literature
| S-EPMC6142310 | biostudies-literature
| S-EPMC8170415 | biostudies-literature
| S-EPMC4945364 | biostudies-literature
| S-EPMC6871578 | biostudies-literature
| S-EPMC6223284 | biostudies-literature
| S-EPMC5331910 | biostudies-literature
| S-EPMC5203817 | biostudies-other
| S-EPMC7643652 | biostudies-literature